...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medicine. >The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis
【24h】

The efficacy and safety of Xiangsha Liujunzi decoction in the treatment of chronic non-atrophic gastritis

机译：湘沙柳金子汤治疗慢性非萎缩性胃炎的疗效和安全性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND:Chronic non-atrophic gastritis is the most common type of chronic gastritis. Even if treated with current standard pharmacotherapy, the efficacy is not very satisfactory due to many factors. Traditional Chinese Medicine decoctions are increasingly used in the treatment of chronic gastritis, and many studies have shown that Xiangsha Liujunzi decoction is effective and safe in the treatment of chronic non-atrophic gastritis. However, it is controversy if Xiangsha Liujunzi decoction can provide an evidence-based clinical efficacy and safety in the treatment of chronic non-atrophic gastritis.METHODS:We will go through 8 databases, and conduct a systematic review of Xiangsha Liujunzi decoction and health-related outcomes in chronic non-atrophic gastritis patients according to the Preferred Reporting Items for Systematic Reviews. The primary objective is to assess the impact of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines on clinical outcomes relevant to chronic non-atrophic gastritis patients, such as clinical effective rate,Helicobacter pylori eradication rate, efficacy under endoscopy, 1-year recurrent rate, and number of reported adverse events. Cochrane Risk Assessment Tool will be used to assess the quality of eligible studies according to the Cochrane handbook.RESULTS:The results of this systematic review will provide a synthesis of current evidence of Xiangsha Liujunzi decoction and we have a specific opportunity to determine the efficacy and safety of it.CONCLUSION:This study will explore whether or not Xiangsha Liujunzi decoction can be used as one of the complementary and alternative therapies in the treatment of chronic non-atrophic gastritis.REGISTRATION NUMBER:Identifier: DOI 10.17605/OSF.IO/TX27U (https://osf.io/tx27u/).Copyright ? 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
机译：背景：慢性非萎缩性胃炎是最常见的慢性胃炎。即使用目前的标准药物治疗治疗，由于许多因素，疗效也不令人满意。中药爆炸越来越多地用于治疗慢性胃炎，许多研究表明，湘沙柳金子汤是有效和安全的慢性非萎缩性胃炎。然而，如果湘沙柳金子汤可以提供慢性非萎缩胃炎的循证临床疗效和安全性，这是争议。方法：我们将经过8个数据库，并对湘沙柳金子汤和健康进行系统审查慢性非萎缩性胃炎患者的相关结果根据首选的系统评价报告项目。主要目标是评估首选报告项目对系统评价和荟萃分析的影响，以临床结果对慢性非萎缩性胃炎患者有关的临床结果，如临床有效率，幽门螺杆菌根除率，内窥镜下的疗效，1年经常性率，以及报告的不良事件的数量。 Cochrane风险评估工具将用于评估根据Cochrane手册的符合条件的研究质量。结果：该系统审查的结果将提供湘沙柳金子汤的现有证据的合成，我们有一个具体的机会来确定疗效和效力安全性。结论：本研究将探讨湘沙柳金子汤是否可作为治疗慢性非萎缩性胃炎的互补和替代疗法之一。重复编号：标识符：DOI 10.17605 / OSF.IO / TX27U （https://osf.io/tx27u/).copyight？ 2021提交人。由Wolters Kluwer Health，Inc。出版

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号